Novo Nordisk Announces Annual General Meeting Date and Proposals for Board Re-election

(IN BRIEF) Novo Nordisk A/S has announced the date for its Annual General Meeting, scheduled for Thursday, March 21, 2024, at 14:00 CET. The meeting will be held partially electronically, allowing shareholders to participate either in person at Bella Center in Copenhagen or virtually via an IT application. The Board of Directors proposes the re-election of Helge Lund as Chair and Henrik Poulsen as Vice Chair, along with the re-election of several other Board members. Novo Nordisk, a global healthcare company, emphasizes its commitment to driving change to combat serious chronic diseases, particularly in the field of diabetes. With approximately 63,400 employees worldwide, Novo Nordisk aims to pioneer scientific breakthroughs and expand access to its medicines to improve healthcare globally.

(PRESS RELEASE) BAGSVÆRD, 22-Feb-2024 — /EuropaWire/ —

The Annual General Meeting of Novo Nordisk A/S will be held on:

Thursday 21 March 2024 at 14.00 (CET)

The Annual General Meeting is held as a partially electronic general meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, DK-2300 Copenhagen S, Denmark or participating virtually via an IT application. We encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting.

Also, Novo Nordisk offers the possibility of viewing the Annual General Meeting via live webcast on Novo Nordisk’s website.

Please refer to the notice for further information. The notice for the Annual General Meeting, including Appendix: Candidates for the Board of Directors, is enclosed.

BOARD OF DIRECTORS
All Board members elected by the Annual General Meeting are up for election.

The Board of Directors proposes re-election of Helge Lund as chair of the Board and re-election of Henrik Poulsen as vice chair. Moreover, the Board proposes re-election of the following Board members: Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Kasim Kutay, Christina Law and Martin Mackay as members of the Board.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 63,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Novo Nordisk Announces Annual General Meeting Date and Proposals for Board Re-election

SEARCH 30,000+ EUROPEAN PRESS RELEASES

About EuropaWire

PRs by Dates

Industries & Countries

Archived PRs

Recent PRs

POPULAR TAGS

Links